Gilead’s Yescarta® (axicabtagene ciloleucel) has been approved to treat adults diagnosed with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.

• Originally FDA approved in 2017, Yescarta is a chimeric antigen receptor T-cell (CAR-T) therapy. CAR-T treatments are created by modifying a donation of the patient’s own T-cells, a type of immune cell, to target cancer. Dosing varies per patient.
• Yescarta is also indicated to treat relapsed or refractory large B-cell lymphoma or follicular lymphoma in adults who have had two or more lines of systemic therapy.